CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer. (6th September 2011)

• Record Type: Journal Article
• Authors: Girgis, Mark D.; Olafsen, Tove; Kenanova, Vania; McCabe, Katelyn E.; Wu, Anna M.; Tomlinson, James S.
• Other Names: Van Heertum Ronald L. Academic Editor.
• Is Part Of: International journal of molecular imaging. Volume 2011(2011)
• Publication Date: 2011-09-06
• Subjects: Molecular diagnosis -- Periodicals; Molecular probes -- Diagnostic use -- Periodicals; Diagnostic imaging -- Periodicals; Molecular Imaging; Diagnostic imaging; Molecular diagnosis; Electronic journals; Periodicals; Periodicals; 616.0757
• DOI: 10.1155/2011/834515
• Languages: English
• ISSNs: 2090-1712

Abstract

Abstract : Introduction . Sensitive and specific imaging of pancreas cancer are necessary for accurate diagnosis, staging, and treatment. The vast majority of pancreas cancers express the carbohydrate tumor antigen CA19-9. The goal of this study was to determine the potential to target CA19-9 with a radiolabeled anti-CA19-9 antibody for imaging pancreas cancer. Methods . CA19-9 was quantified using flow cytometry on human pancreas cancer cell lines. An intact murine anti-CA19-9 monoclonal antibody was labeled with a positron emitting radionuclide (Iodine-124) and injected into mice harboring antigen positive and negative xenografts. MicroPET/CT were performed at successive time intervals (72 hours, 96 hours, 120 hours) after injection. Radioactivity was measured in blood and tumor to provide objective confirmation of the images. Results . Antigen expression by flow cytometry revealed approximately 1.3 × 10 6 CA19-9 antigens for the positive cell line and no expression in the negative cell line. Pancreas xenograft imaging with Iodine-124-labeled anti-CA19-9 mAb demonstrated an average tumor to blood ratio of 5 and positive to negative tumor ratio of 20. Conclusion . We show in vivo targeting of our antigen positive xenograft with a radiolabeled anti-CA19-9 antibody. These data demonstrate the potential to achieve anti-CA19-9 antibody based positron emission tomography of pancreas cancer.